Fas drives cell cycle progression in glioma cells via extracellular signal-regulated kinase activation

Cancer Research

Volumn 60, Issue 6, 2000, Pages 1766-1772

  Shinohara, Hisaaki ^a   Yagita, Hideo ^b   Ikawa, Yoji ^a   Oyaizu, Naoki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CASPASE INHIBITOR; FAS ANTIGEN; FAS LIGAND; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE;

APOPTOSIS; ARTICLE; CELL CYCLE; ENZYME ACTIVATION; GLIOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN PHOSPHORYLATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD95; APOPTOSIS; ASPARTIC ACID; CASPASES; CELL CYCLE; CELL SURVIVAL; ENZYME ACTIVATION; ENZYME INHIBITORS; FAS LIGAND PROTEIN; FLAVONOIDS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MAP KINASE SIGNALING SYSTEM; MEMBRANE GLYCOPROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; RECOMBINANT FUSION PROTEINS; RNA, NEOPLASM; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0034653734     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Nagata, S. Apoptosis by death factor. Cell, 88: 355-365, 1997.
2. Lynch, D. H., Ramsdell, F. and Alderson, M. R. Fas, and FasL in the homeostatic regulation of immune response. Immunol. Today, 16: 569-574, 1995.
3. Bellgrau, D., Gold, D., Selawry, H., Moore, J., Franzusoff A., and Duke, R. C. A role for CD95 ligand in preventing graft rejection. Nature (Lond.), 377: 630-632, 1995.
4. Griffith, T. S., Brunner, T., Flether, S. M., Green, D. R., and Ferguson, T. A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science (Washington DC), 270: 1189-1192, 1995.
5. O'Connell, J., O'Sullivan, G. C., Collins, J. K., and Shanahan, F. The Fas counter-attack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med., 184: 1075-1082, 1996.
6. Hahne, M., Rimoldi, D., Schroter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., Cerottini, J-C., and Tschopp, J. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science (Washington DC), 274: 1363-1366, 1996.
7. Niehans, G. A., Brunner, T., Frizelle, S. P., Liston, J. C., Salerno, C. T., Knapp, D. J., Green, D. R., and Kratzke, R. A. Human lung carcinoma express Fas ligand. Cancer Res., 57: 1007-1012, 1997.
8. Saas, P., Walker, P. R., Hahne, M., Quiqerez, A-L., Schnuriger, V., Perrin, G., French, L., Van Meir, E. G., Tribolet, N. D., Tschopp, J., and Dietrich, P-Y. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J. Clin. Invest., 99: 1173-1178, 1997.
9. Ashkenazi, A., and Dixit, V. M. Death receptors: signaling and modulation. Science (Washington DC), 281: 1305-1308, 1998.
10. Juo, P., Kuo, C. J., Rreynolds, S. E., Konz, R. F., Raingeaud, J., Davis, R. J., Biemann, H-P., and Blenis, J. Fas activation of the p38 mitogen-activated protein kinase signaling pathway requires ICE/CED-3 family proteases. Mol. Cell. Biol., 17: 24-35, 1997.
11. Toyoshima, F., Moriguchi, T., and Nishida, E. Fas induces cytoplasmic apoptosis responses and activation of the MKK-7JNK/SAPK and MKK6-p38 pathways independent of CPP32-like proteases. J. Cell. Biol., 139: 1005-1015, 1997.
12. Deak, J. C., Cross, J. V., Lewis, M., Qian, Y., Parrott, L. A., Distelhorst, C. W., and Templeton, D. J. Fas-induced proteolytic activation and intracellular redistribution of the stress-signaling kinase MEKK1. Proc. Natl. Acad. Sci. USA, 95: 5595-5600, 1998.
13. Yang, X., Khosravi-Far, R., Chang, H. Y., and Baltimore, D. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell, 89: 1067-1076, 1997.
14. Goillot, E., Raingeaud, J., Ranger, A., Tepper, R. I., Davis, R. J., Harlow, E., and Sanchez, I. Mitogen-activated protein kinase-mediated Fas apoptotic signaling pathway. Proc. Natl. Acad. Sci. USA, 94: 3302-3307, 1997.
15. Rudel, T., and Bokoch, G. M. Membrane and morphological changes in apoptotic cells regulated by caspase-mediated activation of PAK2. Science (Washington DC), 276: 1571-1574, 1997.
16. Lenczowski, J. M., Dominguez, L., Eder, A. M., King, L. B., Zacharchuk, C. M., and Ashwell, J. D. Lack of a role for Jun kinase and AP-1 in Fas-induced apoptosis. Mol. Cell. Biol., 17: 170-181, 1997.
17. Chang, H. Y., Nishitoh, H., Yang, X., Ichijo, H., and Baltimore, D. Activation of apoptosis signal-regulating kinase1 (ASK1) by the adapter protein Daxx. Science (Washington DC), 281: 1860-1863, 1998.
18. Alderson, M. R., Armitage, R. J., Maraskovsky, E., W. Tough, T., Roux, E., Schooley, K., Ramsdell, F., and Lynch, D. H. Fas transduces activation signals in normal human T lymphocytes. J. Exp. Med., 178: 2231-2235, 1993.
19. Owen-Schaub, L. B., Radinsky, R., Kruzel, E., Berry, K., and Yonehara, S. Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res., 54: 1580-1586, 1994.
20. Lachman, L. B., Brown, D. C., and Dinarello, C. A. Growth promoting effect of recombinant interleukin 1 and tumor necrosis factor for a human astrocytoma cell line. J. Immunol., 138: 2913-2916, 1987.
21. Aggarwal, B. B., Schwarz, L., Hogan, M. E., and Rando, R. F. Triple helix-forming oligodeoxyribonucleotides targeted to the human tumor necrosis factor (TNF) gene inhibit TNF production and block the TNF-dependent growth of human glioblastoma tumor cells. Cancer Res., 56: 5156-5164, 1996.
22. Weller, M., Frei, K., Groscurth, P., Krammer, P. H., Yonekawa, Y., and Fontana, A. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. J. Clin. Invest., 94: 954-964, 1994.
23. Kayagaki, N., Kawasaki, A., Ebata, H., Ohtomo, S., Inoue, S., Yoshino, K., Okumura, K., and Yagita, H. Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med., 182: 1777-1783, 1995.
24. L can inhibit apoptosis in cells that have undergone Fas-induced protease activation. Proc. Natl. Acad. Sci. USA. 94: 3759-3764, 1997.
25. Yoshida, T., Sato, A., and Ikawa, Y. Both human Fas and chimeric Fas/TNFR-1 mediate complete cell death in murine NIH/3T3 cells with less distinct nuclear fragmentation. Proc. Japan Acad., 72: 16-21, 1996.
26. Toba, K., Winton, E. F., Koike, T., and Shibata, A. Simultaneous three-color analysis of the surface phenotype and DNA-RNA quantitation using amino-actinomycin D and pyronin Y. J. Immunol. Methods, 182: 193-207, 1995.
27. mapk are required for fibroblast proliferation. Proc. Natl. Acad. Sci. USA, 90: 8319-8323, 1993.
28. Sebolt-Leopold, J. S., Dudley, D. T., Herrera, R., Becelaere, K. V., Wiland, A., Gowan, R. C., Tecle, H., Barrett, S. D., Bridges, A., Przybranowski, S., Leopold, W. R., and Saltiel, A. R. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat. Med., 5: 810-816, 1999.
29. Cowley, S., Paterson, H., Kemp, P., and Marshall, C. J. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH3T3 cells. Cell, 77: 841-852, 1994.
30. Mansour, S. J., Matten, W. T., Hermann, A. S., Candia, J. M., Rong, S., Woude, V., and Ahn, N. G. Transformation of mammalian cells by constitutively activate MAP kinase kinase. Science (Washington DC), 265: 966-970, 1994.
31. Mandell, J. W., Hussaini, I. M., Zecevic, M., Weber, M. J., and VandenBerg, S. R. In situ visualization of intratumor growth factor signaling. Immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms. Am. J. Pathol., 153: 1411-1423, 1998.
32. Gulbins, E., Bissonnette, R., Mahboubi, A., Martin, S., Nishioka, W., Brunner, T., Baier, G., Baier-Bitterlich, G., Byrd, C., Lang, F., Kolesnick, R., Altman, A., and Green, D. Fas-induced apoptosis is mediated via a ceramide-initiated RAS signaling pathway. Immunity. 2: 341-351, 1995.
33. Huang, S., Jiang, Y., Li, Z., Nishida, E., Marthias, P., Lin, S., Ulevitch, R. J., Nemerow, G. R., and Han, J. Apoptosis signaling pathway in T cells is composed of ICE/Ced-3 family proteases and MAP kinase kinase 6b. Immunity, 6: 739-749, 1997.
34. Xia, Z., Dickens, M., Raingeard, J., Davis, R. J., and Greenberg, M. E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science (Washington DC), 270: 1326-1331, 1995.
35. Sugawara, T., Moriguchi, T., Nishida, E., and Takahama, Y. Differential role of ERK and p38 MAP kinase pathways in positive and negative selection of T lymphocytes. Immunity, 9: 565-574, 1998.
36. Zhang, J., Cado, D., Chen, A., Kabra, N. H., and Winoto, A. Fas-mediated apoptosis and activation-induced T-cell proliferation in mice lacking FADD/Mort1. Nature (Lond.), 392: 296-300, 1998.
37. Newton, K., Harris, A. W., Bath, M. L., Smith, K. G. C., and Strasser, A. A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J., 17: 706-718, 1998.
38. Suda, T., Okazaki, T., Naito, Y., Yokota, T., Arai, N., Ozaki, S., Nakao, K., and Nagata, S. Expression of the Fas ligand in cells of T cell lineage. J. Immunol., 154: 3806-3813, 1995.
39. D'Souza, S. D., Bonetti, B., Balasingam, V., Cashman, N. R., Barker, P. A., Troutt, A. B., Raine, C. S., and Antel, J. P. Multiple sclerosis: Fas signaling in oligodendrocyte cell death. J. Exp. Med., 184: 2361-2370, 1996.
40. Gratas, C., Tohma, Y., Vanmeir, E. G., Klein, M., Tenan, M., Ishii, N., Tachibana, O., Kleihues, P., and Ohgaki, H. Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol., 7: 863-869, 1997.